Review

Targeting Tumors Using Peptides

Pablo Scodeller [1],* and Eliana K. Asciutto [2]

[1] Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu 50411, Estonia
[2] School of Science and Technology, National University of San Martin (UNSAM) and CONICET, Campus
     Migueletes, 25 de Mayo y Francia, San Martín, Buenos Aires CP 1650, Argentina; easciutto@unsam.edu.ar
*   Correspondence: pablo.david.scodeller@ut.ee

check for updates

Abstract: To penetrate solid tumors, low molecular weight (Mw < 10 KDa) compounds have
an edge over antibodies: their higher penetration because of their small size. Because of the
dense stroma and high interstitial fluid pressure of solid tumors, the penetration of higher Mw
compounds is unfavored and being small thus becomes an advantage. This review covers a wide
range of peptidic ligands—linear, cyclic, macrocyclic and cyclotidic peptides—to target tumors: We
describe the main tools to identify peptides experimentally, such as phage display, and the possible
chemical modifications to enhance the properties of the identified peptides. We also review in silico
identification of peptides and the most salient non-peptidic ligands in clinical stages. We later focus
the attention on the current validated ligands available to target different tumor compartments: blood
vessels, extracelullar matrix, and tumor associated macrophages. The clinical advances and failures
of these ligands and their therapeutic conjugates will be discussed. We aim to present the reader
with the state-of-the-art in targeting tumors, by using low Mw molecules, and the tools to identify
new ligands.

Keywords: phage display; peptides; peptide-drug conjugates; small molecules; tumor associated
macrophages; extracellular matrix

1. The Need for Low Mw Ligands

Low Mw entities offer fundamental advantages over high Mw entities like antibodies or
nanoparticles [1,2]. Many tumors like pancreatic and breast dramatically overexpress stromal
components, mostly collagen and hyaluronic acid [3–5]. This represents a serious barrier that
impedes the penetration of large molecules (such as antibodies), because of their lower diffusion
coefficient and the high interstitial fluid pressure [6–8].

The very high affinity of antibodies is also a limitation to their penetration in tumors, due to a
phenomenon known as affinity site barrier [9], which means that the administered antibody binds to
the first receptor it encounters and thus cannot explore beyond that. To prevent the affinity binding
site barrier, the binding constant K_D should not be lower than 10^{-9}M, since tumor accumulation does
not increase beyond that K_D [9].

If we take into account that in a tumor the number of receptors available to peptides from the
circulation is normally low (picomoles per gram of tumor [10]), we need to consider using a potent
therapeutic/diagnostic companion for the targeting ligand.

Targeted therapies must consider both tumor heterogeneity and inter-patient heterogeneity.
In designing mouse-based preclinical studies, the targeting ligand should be chosen based on the tumor
type and a marker consensuated to be over-expressed in that cancer in mice and humans. For clinical
studies, the over-expression of the marker intended to target should be confirmed for each patient
individually, by biopsies and immunohistochemical detection.

2. Identification of Peptides by Biopanning

Peptide binders can be identified using peptide libraries displayed on bacteriophage (hereafter referred to as "phage"). In 1985, Smith showed that fusion proteins can be expressed on the capsid of phage virus by introducing foreign DNA material in the phage [11]. This opened the door to biopanning studies to screen and select for binding peptides [12] and also antibodies [13].

Initially, the peptide phage libraries consisted of a linear chain of 6 variable aminoacid residues, X_6 (where X denotes a random aminoacid) [14]. Later, the random sequence was inserted between two cysteines to obtain cysteine-to-cysteine disulfide cyclized peptides to reduce conformers and improve affinity. The first cysteine-bridged peptide phage library, developed in 1992 by DeGrado and co-workers [15], was of the type CX_6C and was displayed on the filamentous bacteriophage M13. Because random stop codons occur, this library also gives rise to the linear peptides CX_6 or shorter. In the T7 bacteriophage system, the variable foreign peptide is inserted at the C-terminus of the coat protein 10A, while in the filamentous M13 bacteriophage, the insert is placed on the N-terminus of the protein III [16].

In 1996, Ruoslahti and Pasqualini introduced in vivo biopanning using peptide phage display [17] and showed that each organ has a different vascular "zip code" that can be probed with the phage library. In in vivo tumor biopanning, the phage library in PBS is injected into a tumor-bearing mouse, allowed to circulate, and is later followed by perfusion to remove unbound and weakly bound phage. The phage which remain in the tissue after perfusion are the strongest binders and are easily amplified by incubating a lysate of the tumor with a suspension containing the bacterial phage host.

Multiple rounds of biopanning are carried out in this way to enrich in the strong binders. This methodology, which is described in fine detail elsewhere [18] has yielded a large collection of tumor-homing peptides to date [19], and we have also used it to screen mice with Alzheimer's disease [20] or penetrating brain injuries [21].

In vivo biopanning has also been performed in humans, in terminal cancer patients [22]. In vivo phage display from biopsied human tissue was pioneered by Pasqualini and coworkers in 2002 on a patient with B cell malignancy refractory to chemotherapy and with infiltration of tumor cells in the bone marrow [22]. The authors used a CX_7C library expressed on M13 phage and intravenously infused the patient with the phage library dispersed in 100 mL of saline, and after 15 min of circulation, the tissues were biopsied, the phage were recovered and the sequences analyzed. The authors recovered a phage clone (sequence: CGRRAGGSC) that bound to interleukin 11 receptor alpha (IL-11Rα) which was overexpressed in the prostate. In subsequent studies, this clone was shown to bind to human samples of prostate cancer from 90 patients [23] and to home to IL-11Rα in prostate tumors in mice [24]. The sequence was validated in vitro as a peptide when the authors showed the cytotoxicity to cultured prostate cancer cells of the peptide conjugated to a proapoptotic moiety [23]. In a subsequent in vivo biopanning study in humans in 2011 [25], Pasqualini, Arap and coworkers used the pool recovered from the patient of 2002 for two further rounds of in vivo selection, serially, in two patients with metastatic prostate cancer. Using high throughput sequencing they analyzed 2.4×10^6 tripeptide motifs recovered from the biopsied tissues and found that the organs had preferences for particular motifs. There was no mention as to whether the original isolated clone CGRRAGGSC was enriched during these additional two rounds. Intriguingly, there was also no mention to the presence of the known integrin-targeting tripeptide RGD.

2.1. Enhancement of Identified Binding Motifs

Short (defined here as being ≤ 10 residues) linear peptides generally possess a low binding affinity, given their high conformational freedom, and they also display poor resistance to proteolytic degradation. However, it is possible to add modifications to the identified binding sequence in order to circumvent both of these problems.

Cyclization of a linear sequence constrains the peptide and can increase the affinity [14,26,27]. A simple way to achieve cyclization is through the addition of N-terminal and C-terminal cysteines

that are intentionally oxidized during the peptide synthesis to form a disulfide bond. An alternative to forming a loop between the ends of the peptide is to perform N-terminal to C-terminal cyclization, also known as backbone or head-to-tail cyclization. This not only constrains the peptide but also provides a higher resistance to proteases [28,29].

The term stapling refers to forming a covalently linked hydrocarbon bridge between two non-natural O-allylserine residues inserted in the peptide [30]. Stapling is intended to increase the rigidity of an α helix in a peptide, hence the linkage must be spaced apart in a way that it does not disturb the twist of the helix. Stapling reduces the number of conformers, increases serum stability and in some cases improves cell permeability, depending on the hydrophobicity of the peptide and the staple [31]. Nuclear magnetic resonance (NMR) spectroscopy, a powerful experimental tool to assess the structure and conformation of proteins and peptides in solution, can be used to corroborate the stabilization generated by the staple [30]. The company Aileron Therapeutics (Watertown, MA, USA) has developed a stapled, cell-permeable, alpha helical peptide, called ALRN-6924, which blocks the tumor-promoting interaction that occurs between p53 and its endogenous inhibitor. The company has an ongoing clinical trial with ALRN-6924 alone or in combination with the chemotherapeutic drug cytarabine, for acute myeloid leukemia (clinical trial identifier: NCT02909972).

The binding of low affinity ligands can also be increased by increasing their avidity, i.e., presenting the ligands in a multivalent manner, as in dimers, trimers [32] or multibranched star shapes [33]. In this approach the binding constant of the multivalent ligand scales with the number of valencies [34].

An appealing and nature-inspired approach to increase affinity, stability and provide oral activity, is to graft the binding motif to natural peptidic structures known as cyclotides. Cyclotides are naturally occurring peptides in plants that were discovered by Craik in the 1990s [35]. These peptides are head-to-tail cyclized and are additionally stabilized by disulfide bonds between non contiguous cysteines. This particular structure endows them with an unprecedented rigidity and makes them resistant to proteases and high temperatures [36–39]. An example of a cyclotide is the sunflower trypsin inhibitor-1 (SFTI-1), a 14 aminoacid residue peptide consisting of two loops separated by one disulfide bond. One of its loops inhibits the activity of trypsin and pepsin, thus further increasing the endurance of the peptide to proteases and rendering it orally active [40,41]. It has been reported that known binding motifs can be grafted to the second loop of SFTI-1 amplifying the affinity of the motifs for their receptors while preserving the favorable features of the parental SFTI-1 [36,41,42]. Another cyclotide, called Kalata B1, derived from the kalata plant, presents a structure of 29 aminoacid residues knotted by three disulfide bridges [35]. Kalata B1 is resistant to high temperatures and to the conditions found in the gastrointestinal tract. Infusions of the kalata plant are used in the congo region in Africa by pregnant women to induce labour, because of the ability of Kalata B1 to induce uterine contractions.

Peptidic ligands that do not withstand the gastrointestinal tract need to be administered in the blood and generally present a fast renal clearance because of their low molecular weight. A short blood half-life is an advantage for radioligands, which are used in radiotherapy to concentrate alpha or beta radiation in the tumor [43] but induce unwanted damage while they circulate.

The blood half-life of a peptide can be extended by conjugating it to a higher Mw long-circulating molecule, such as polyethylene glycol (PEG) [44,45]. The tumor penetration, in lymphoma-bearing mice, of a tumor-targeting peptide [46] conjugated to PEGs of different Mw (ranging from 40 KDa to 150 KDa) scaled linearly with the Mw of PEG [45], despite the higher Mw and hence slower diffusion. However, the authors did not include the non PEGylated peptide in their study and lymphoma is not stroma-dense, so the advantages of PEGylating a peptide for targeting solid tumors with aberrant stroma remain to be seen.

A widely used approach to extend a peptide's half life exploits the long-circulating capacity of serum albumin and relies on coupling an albumin-binding moiety to the peptide, such as Evans blue [47,48], fatty acids [49,50], short albumin-binding peptides [51], or albumin-reacting moieties like an extra cysteine [52] or a maleimide group [48] to form a disulfide bond with albumin-Cys34. Another strategy relies on coupling to the peptide a small molecule for binding to another long-lived

serum protein, transthyretin [53]. However, it must be noted that by associating the peptide with a long-circulating molecule so that the Mw of the ensemble is above renal cutoff, the ensemble is no longer a low Mw entity.

2.2. Alternative Biopanning Strategies

More sophisticated biopanning strategies have been devised to identify peptides with higher affinity and stability. To address the issue of the poor proteolytic stability of peptidic ligands, in 1996, Schumacher and co-workers proposed a method of identifying ᴅ-peptidic binders, since ᴅ-aminoacids are not recognized by mammalian proteases. Their elegant approach, called mirror image phage display [54], consisted of screening a ᴅ-aminoacids containing protein of interest with a library of natural ʟ-peptides. The ᴅ-enantiomer of the identified ʟ-peptide binder was then shown to bind to the natural ʟ-enantiomer protein. The drawback of this approach is that because it is performed on ᴅ-proteins, it cannot be carried out in vivo.

After the initial linear and disulfide-cyclized peptide libraries, new strategies appeared to identify constrained peptides with higher affinity for their targets. The first of such developments was introduced by Heinis, Winter and co-workers in 2009, with bi-cyclic peptide libraries [55]. In this filamentous bacteriophage library, the random chain of aminoacids contains three cysteines, two in the ends and one in the middle. The phage library is then chemically modified to link the three cysteines with a three-armed linker [tris-(bromomethyl)benzene] to form a macrocycle that contains two loops. In the first proof of concept, this approach was used to identify a low nM affinity ligand to kallikrein [55], an enzyme implicated in human cancer [56]. Although oral activity has not yet been reported, these high affinity bicyclic peptides have enormous pharmacological potential, because of their selectivity and affinity to the receptor and a superior tumor penetration compared to antibodies. This technology has spawned the company Bicycle Therapeutics (Cambridge, U.K.) which uses this screening platform to develop new drugs.

3. In Silico Identification of Peptides

Biopanning is not the only path to identify a good peptidic ligand. Several peptides have been identified in silico using random generation algorithms, modification of existing databases or conceived by imitating protein fragments known to bind a desired receptor.

Crude random generations algorithms are the simplest methods in which, given a desired length for a peptide ligand, all the resulting possible combinations for sequence and structure are tested. The number of possible sequence combinations for a peptide with length n is 20^n; and for each combination, an extensive number of possible structural conformations exist, increasing enormously the number of peptide conformations. Increasing the length of the peptide, n, not only increases the number of possible combinations of amino acids, but also the number of possible peptide bond torsions, that is, increases the number of degrees of freedom of the system. It is evident that a random generated library can be extremely computationally demanding, even for very small peptides. However, using this technique, Panyayai and coworkers reported WCW as the tripeptide with best inhibitory activity to angiotensin-I converting enzyme (ACE) [57], an enzyme with tumor-promoting roles [58], and the inhibition of which shows reduced mortality and recurrence in many cancer types [59]. In their work, they started with a random library of 8000 tripeptides generated using a python algorithm. This library was docked to the ACE structure and the 600 best scoring compounds were selected. After an analysis of site occupancy and physical properties of each candidate they finally selected five tripeptides to test experimentally, and WCW resulted as the best candidate showing an IC50 value of 49 μM. A similar procedure was applied by Mollica and coworkers to discover novel tripeptides with the ability of inhibiting human α-glucosidase enzyme [60]. The authors generated a library with all combinatorial possibilities for a tripeptide and then followed a process of docking, molecular mechanics/generalized Born surface area (MM/GBSA) refinement, and molecular dynamics using several components of the

Schrödinger package [61–63]. The resulting four peptides from this method inhibited α-glucosidase with an inhibitory potency equivalent to the one associated with the peptide used as template, acarbose.

In the mentioned works, the number of initial candidates generated by the random algorithm were reduced using mainly physical and chemical principles. A different approach was undertaken by Michaeli and coworkers [64]. They used the risk-adjusted design algorithm [65], a finance-based algorithm, to computationally design linear and cyclic peptides targeting proteins MD2 and CD14, both co-receptors of human toll-like receptor 4, which is associated with chemoresistance in breast cancer [66]. The algorithm reduces the number of candidates by assigning them a "reward" or a "risk". The rewards are calculated using an energy binding approximation, while the risk is related with possible steric clashes that could occur as a result of a particular substitution. With this algorithm, the authors could predict a total of 26 cyclic and 27 linear peptides that bind to the human TLR4 co-receptor complexes.

Another strategy of in silico peptide design is to use a pre-existing database instead of generating one. A good example of this approach is that used by Vukic et al., identifying a set of milk derived di- and tri-peptides with high antihypertensive activity for the angiotensin-I-converting enzyme [67]. They used an ACE-inhibiting milk peptide database, containing aminoacids sequences and activities, and applied the CoMFA model [68,69] combined with molecular docking techniques to do the search. CoMFA model is based on a 3D quantitative structure activity relationship (3D-QSAR) [70,71] that employs both interactive graphics and statistical tools for correlating geometries and physical properties of molecules with their biological activity. Although 3D-QSAR models for ligand predictions have been used for more than three decades now, its use with peptides is very recent, since older models were not capable of dealing with the peptide's high conformational flexibility.

A useful in silico peptide design strategy consists of simulating protein fragments known to bind a desired receptor. A good example of this methodology is the prediction and design of two peptides, P109 and P110 based on a thorough study of the interactions between the NTF2-like domain of G3BP (overexpressed in human tumors [72]) and the SH3 domain of RasGAP [73]. Another example is the work by Geng et al. The authors designed two 27-mer peptides to target the extracellular domain of HER2 protein using a combination protocol of molecular dynamics, MM/GBSA binding free energy calculations, and binding free energy decomposition analysis [74]. The design was based on the known interactions between a previously reported affibody to HER2 (ZHER2:342) [75] and HER2 and a later rational structural modification. Basically, important identified binding residues were kept and linked together with glycine residues according to previously calculated distances.

Protein-Peptide Docking Methods

Success of in silico virtual peptide library screening strongly depends on the efficiency of the docking techniques employed to select the best candidates. Current peptide docking techniques can be divided into two categories: *local peptide docking*, wherein information of the binding pocket is available and docking focuses on finding the binding modes of a given peptide at the known binding pocket/site of a target macromolecule [76–78]; and *global peptide docking*, in which no information on the binding site is available. Local peptide docking is challenging due to the high flexibility of peptides, and consequently large number of possible values for the several torsion angles between peptide bonds, but the real challenge occurs in *global peptide docking*, where no information regarding the location of the binding region is available, and thus, as the name implies, the search has to be global, around the entire surface of the macromolecule. This type of search is referred to as 'blind docking'. Very few works deal with peptide blind docking, in which a flexible peptide is docked to a target macromolecule without prior knowledge of the binding site.

The first successful study was performed by Hetenyi and coworkers using the Autodock package for blind docking of di- and tri-peptides [79]. The method was powerful in locating the binding pockets and binding orientations for protein-small peptides complexes.

For medium size peptides (up to nine residues) successful attempts of blind docking were achieved by some of the second generation docking techniques (called "ensemble docking") [80–82]. One of them, HPEPDOCK81, treats the peptide flexibility using a hierarchical algorithm that models peptide conformations and progressive global sampling of binding orientations. Using HPEPDOCK, Srinivasan et al. designed de-novo tripeptides that bound to a mutant form of the copper/zinc dismutase SOD1 [83], an enzyme which has been assigned pro-tumoral roles [84].

The latest generation of docking methods includes full peptide flexibility, sampled at the same time as the global protein search is performed. These methods are called *de-novo* docking methods. Some of them also have the ability of making blind docking. One of these *de-novo* docking methods, AnchorDock [85], restricts the docking search to the most relevant parts of the conformational space. Preliminary restrictions are performed by identifying anchoring spots on the protein surface in a first step, and then performing simulated annealing molecular dynamics around the predicted protein anchoring spots.

Recently, Kurcinski et al. developed a web server interface (The CABS-dock protocol) that performs *de novo* blind docking for 5–15 aminoacid peptides [86,87]. The method also allows to exclude domains in the macromolecule that are known to not participate in the studied docking problem with the aim of reducing conformational space search. An advantage of this protocol is that it is very user friendly, and only requires as inputs a PDB for the receptor and the sequence of the peptide. To improve the quality of the method some extensions were added, as a refinement step using molecular dynamics and the possibility of incorporation of experimental data [87]. Zhang [88] and coworkers developed a new version of Autodock, also oriented to *de novo* peptide blind docking; the software is called AutoDock CrankPeP (ADCP). It makes use of CRANKITE [89], a software package that samples the conformational space of proteins using a Metropolis Monte Carlo method. In ADCP, CRANKITE is combined with the grid-based AutoDock representation of a rigid receptor to optimize at the same time peptide conformations and peptide-receptor interactions. ADCP showed a success rate greater than 85% on the LEADS-PEP dataset when considering the top 10 predictions. It is also able to dock peptides with up to 20 amino acids to their receptors.

De novo methods are currently the most accurate ones for peptide blind docking or binding pocket prediction, as are also less affected by the peptide's length. A particular challenging case appears when the binding site is located at an interface. To address this problem there exist a variety of tools as CASTp [90], MAPPIS [91], MolSurfer [92], and ProFace [93], all designed to find residues at interfaces that show strong interactions between proteins. Regarding peptides, Wang and coworkers [94] found short peptides that target programmed cell death protein 1 (PD-1) to inhibit its binding to programmed cell death ligand 1 (PD-L1). The unknown binding pocket of PD-1 is in fact part of PD1/PD-L1 interface. The authors used all of the four mentioned packages: CASTp, MAPPIS, MolSurfer, and ProFace and selected the residues that were common findings between all the methods as residues defining the binding site based on interactions. As a result, peptides that bind to the PD-1 receptor with moderate affinity were found confirming, at least in part, that the proposed binding pocket was correct.

The virtual screening methods discussed so far make use of different structure determination and docking protocols, but not all of them are freely available. Ansar and coworkers [95] developed a graphical user interface-based pipeline that integrates different existent tools for performing the complete process of virtual screening of peptides. The pipeline is called PepVis, and it features both ensemble and flexible de novo docking protocols. The tools included in PepVis are freely available tools and show a good performance in benchmarking of protein–peptide docking studies (i.e., ModPep [96] + Vina [97]). The docking protocols we have exposed are summarized in Table 1.

Table 1. Docking Protocols suitable for blind peptide docking.

Docking Protocol	Description	URL
AutoDock	A parameter set based on the AMBER force field (Cornell et al. 1995) is used. Flexible or fixed torsions for the ligands can be used	http://autodock.scripps.edu/
HPEPDOCK	Peptide flexibility is included as an ensemble of peptide conformations	http://huanglab.phys.hust.edu.cn/hpepdock/
AnchorDock	Uses prior identification of anchoring spots on the protein surface and the peptide is simulated around the predicted spots.	http://dx.doi.org/10.1016/j.str.2015.03.010
CABS-dock	Multiscale procedure using coarse-grained protein model and a Monte Carlo scheme.	http://biocomp.chem.uw.edu.pl/CABSdock
AutoDock CrankPeP	Folds the peptide in the potential energy landscape created by the receptor.	http://adcp.scripps.edu/
PepVis	Pipeline for automated script generation	https://github.com/inpacdb/PepVis

4. Vascular-Targeting Peptides

Perhaps the most paradigmatic tumor-homing peptide motif is RGD, which targets integrins over-expressed on tumor blood vessels. After identifying fibronectin in 1973 [98], Ruoslahti and collaborators, in 1984, discovered that a small fragment in fibronectin, the RGD motif, was responsible for its binding to cells [99]. In 1985, Ruoslahti and co-workers identified the receptor for RGD, using affinity chromatography, from an extract of osteosarcoma cells [100]. The receptor was a 140 KDa cell surface glycoprotein. That protein identified by Ruoslahti was an integrin, although the name integrin was only introduced a year later by Hynes when he identified another member of the integrin family [101]. The RGD motif was later shown to bind to different members of the integrin family [102].

Interestingly, when biopanning was performed on recombinant $\alpha_5\beta_1$ integrin using a linear X_6 library, the vast majority of the selected binders contained RGD, and one peptide where RGD was contained between two cysteines (presumed to be cyclized) showed stronger binding than the linear ones [14].

A tumor-penetrating version of the RGD peptide was identified in 2009 (denoted iRGD, "i" for internalizing) by in vitro biopanning of the CX_7C library on prostate cancer cells [103]. The ligand iRGD contains, besides the integrin-binding motif, a C-terminal sequence that binds to neuropilin-1 (NRP-1). The NRP-1-binding motif needs to be on the C-terminus for binding to occur, and this condition was termed the "C-end rule" or CendR. It was possible to encounter this condition because the T7 bacteriophage was used for the screens, where the insert is on the C-terminus of the coat protein. The NRP-1-binding motif is only exposed after proteolytic cleavage, something which is favored in the tumor microenvironment. Binding to NRP-1 triggers tissue penetration of the peptide and drugs administered with it [104,105]. The discoverers of iRGD also reported anti-metastatic properties of the peptide in mouse models of pancreatic and prostate cancer, and the effect was mediated by the binding to NRP-1 [106]. Different research groups over the last 10 years have shown that iRGD enhances drug accumulation and efficacy in a number of tumor models [107–111], and we showed that iRGD also enhances the tumor accumulation of co-administered chemotherapy when it is given intraperitoneally to treat metastases in the peritoneum [112]. A company called DrugCendR (La Jolla, CA, USA) was founded by Ruoslahti to translate the oncological applications of iRGD, and in 2018 iRGD entered phase I clinical trials as an additive to gemcitabine and abraxane for pancreatic cancer (clinical trial identifier: NCT03517176).

A head-to-tail cyclized version of RGD was developed by Kessler and collaborators in 1991 [27,113]. The authors introduced a D-aminoacid that induced a defined conformation and this facilitated head-to-tail cyclization. It was the cyclization and not the introduction of additional D-aminoacids that potently increased the binding activity of this cyclic RGD. The most used and studied variant of

the cyclized RGD is denoted cyclo(RGDfV), where f is D-phenylalanine and V is valine. The peptide cyclo(RGDfV) was later commercialized for research use under the name cilengitide. Cilengitide alone proved to be effective in reducing glioblastoma in mice [114] and also in phase I and II clinical trials [115], presumably because of its anti-angiogenic effects [113]. However, in phase III clinical trials cilengitide did not show an effect on survival [116] and its development was halted. The reasons for the failure of this phase III were suggested to be related to the poor pharmacokinetics of this small peptide (which was given intravenously) and an ineffective administration regime [117]. The milestones in the genesis and evolution of RGD in tumor targeting are schematized in Figure 1.


Figure 1. Milestones in the genesis and evolution of RGD in tumor targeting.

Recently, an RGD-containing bicyclic peptide was identified by screening a library of 672 synthesized macrocyclic peptides that contained RGD and differed in their cyclization structure. The strongest binder showed a striking 0.4 nM affinity towards $\alpha_v\beta_3$ integrin. The authors showed in vitro binding to receptor-positive cells although information on the peptide's biological effect is still unavailable [118].

Haberkorn et al. have identified an $\alpha_v\beta_6$ binding peptide by screening a phage library based on a sunflower trypsin inhibitor-1 scaffold [119]. The selected peptide included the motif FRGDLMQL and showed strong binding to $\alpha_v\beta_6$ ($K_D \approx 15$ nM). The peptide was used as a radioligand, coupled to a PET-active probe (^{68}Ga) in tandem with the radiotherapeutic agent ^{177}Lu. This peptide-drug conjugate showed selective tumor accumulation in patients with head and neck squamous carcinoma and non-small cell lung cancer, as evidenced through PET imaging, forecasting potential therapeutic success.

Del Gatto et al. have rationally designed an RGD-containing peptide that binds to $\alpha_v\beta_3$ integrin and not to $\alpha_v\beta_5$, by using the X-ray structure of $\alpha_v\beta_3$ complexed with cilengitide and the NMR structure of the disintegrin Echistatin; they named this new peptide RGDechi [120]. RGDechi conjugated to a PET imaging probe homed to $\alpha_v\beta_3$+ tumors and not to $\alpha_v\beta_5$+ tumors [121]. More recently, the same group mapped the interactions between RGDechi and $\alpha_v\beta_3$ by performing NMR spectroscopy of RGDechi and a $\alpha_v\beta_3$-containing cell membrane, and molecular docking studies of this complex [122]. The ability to target $\alpha_v\beta_3$ integrin is important because of its role in tumor angiogenesis and metastasis [123,124].

Stallcup, Ruoslahti, and colleages, identified in 1999 a peptide that binds to the chondroitin sulfate proteoglycan NG2 [125], an attractive target, as it is expressed on angiogenic blood vessels in tumors. In vitro biopanning was carried out using a 10-mer linear phage library on wells coated with recombinant NG2 and after several rounds the peptides TAASGVRSMH and LTLRWVGLMS were enriched. The two phage clones containing those inserts homed to NG2+ tumor vasculature, but not to NG2 knockout tumors; however, the selected motifs were not tested as free peptides. In a 2014 study, the TAASGVRSMH peptide was conjugated to docetaxel-loaded nanoparticles; this guided the nanoparticles to NG2+ vascular pericytes in the tumor and enhanced their efficacy in a model of metastatic melanoma [126].

Another tripeptide motif with well validated tumor vasculature homing is NGR [127]. An NGR-containing phage clone was first isolated by Koivunen and Ruoslahti during in vitro biopanning on $\alpha_5\beta_1$ integrin [14]. The NGR motif binds to integrins with low affinity, but its receptor

is Aminopeptidase N (APN/CD13) [128], a protein which is detectable in tumor vasculature and in angiogenic blood vessels. A disulfide-cyclized peptide containing the NGR motif, CNGRC, conjugated to doxorubicin, was toxic to APN-transfected cancer cells in vitro and not to the non-transfected controls [128].

The vascular-homing peptides described here are summarized in Table 2.

Table 2. Vascular-homing peptides.

Peptide	Sequence/Structure	Ref	Identification	Advantages
iRGD	CRGDKGPDC (disulfide cyclized)	[103]	In vitro phage display	* Tumor-penetrating peptide * Medium-high affinity for $\alpha_v \beta_5$ integrin (K_D: 62nM) and $\alpha_v \beta_3$ integrin (K_D: 18 nM) * Extensively validated in different tumor models * Proven non-immunogenicity in mice * In phase I clinical trials
Cilengitide	RGDfV (head to tail cyclized)	[27]	By rational design based on RGD motif	* High affinity for $\alpha_v \beta_3$ integrin (K_D: 0.58nM) * Safe in humans
SFITGv6	GRCTFRGDLMQLCYPD (head-to-tail cyclized, disulfide bonded)	[119]	In vitro phage display	* High affinity for $\alpha_v \beta_6$ integrin (K_D: 15nM) * Validated applicability in cancer patients
CNGRC	CNGRC (disulfide cyclized)	[128]	In vitro phage display	* Validated in vitro as peptide-drug conjugate * Proven non-immungenicity in mice
RGDechi	Cyclic RGD/echistatin hybrid PubChem CID: 91936353	[120]	By rational design based on cyclic RGD and echistatin	* Validated applicability in PET imaging * Can discriminate between $\alpha_v \beta_3$ and $\alpha_v \beta_5$ integrin

5. Extracellular Matrix-Targeting Peptides

Almost all solid tumors overexpress extracellular matrix (ECM). The ECM components which are over-expressed include collagen, connective tissue growth factor, versican, chondroitin sulfate proteoglycans [129–131] and isoforms and alternatively spliced forms of tenascin-C [132] and fibronectin extra domain B [133].

In 2017 we screened mice with Alzheimer's disease using a CX_7C peptide T7 phage library and collected a peptide named "DAG" (disulfide bonded CDAGRKQKC) that targets connective tissue growth factor (CTGF/CCN2) [20]. The applicability of the DAG peptide was demonstrated for Alzheimer's disease, as we found that CTGF is overexpressed in early and late stages of the disease in mice and also in humans [20]. Besides its presence in the ECM, CTGF is also expressed on endothelial cells, in cancer [134] and in early Alzheimer's disease, thus DAG should be considered both an ECM and a vascular targeting ligand. DAG showed high accumulation in a patient-derived xenograft of glioblastoma, binding to activated astrocytes and extracellular matrix in the tumor. The matricellular protein CTGF is known to be upregulated in several glioblastoma models in mice [135] and also in human brain tumors [136], it is mainly produced by activated astrocytes and represents an attractive target for the treatment of glioblastoma [137].

More recently, a peptide (dubbed PL1) that binds to fibronectin extra domain B (EDB-FN) and tenascin-C was identified by performing in vitro biopanning using a CX_7C phage peptide library on both recombinant proteins [138]. PL1 (sequence: PPRRGLIKLKTS)-conjugated nanoparticles targeted several different intracraneal glioblastomas in mice, which expressed one or both receptors, which are often over expressed also in human brain tumors. In vivo validation of PL1 as a free peptide has not yet been published.

Lu and collaborators identified in 2015 another peptide that binds to EDB-FN [139]. The peptide, termed ZD2 (disulfide-cyclized CTVRTSADC), has an affinity of 11 μM for EDB-FN and was identified by screening a CX_7C commercial M13 phage library on recombinant EDB immobilized on plates.

Conjugates of ZD2 and a ^{68}Ga chelate or Gd-DOTA, are currently being developed by the company Molecular Theranostics (Cleveland, OH, USA) as contrast agents for PET and MRI imaging, respectively, for prostate cancer.

Hamzah and colleagues have attacked the problem of targeting tumor ECM in a clever way [140]. Using a CX_7C library, they performed in vitro biopanning on Matrigel^{TM}. The selected pool after three in vitro rounds was then administered in breast tumor-bearing mice for in vivo biopanning. Four rounds of biopanning yielded the peptide CSGRRSSKC (named CSG). Disulfide cyclized CSG displayed tumor homing in different mouse models and was shown to bind to laminin-nidogen complexes. By performing the phage selection on Matrigel^{TM}, the authors were able to identify a peptide that binds to an ECM target that is not associated with blood vessels or in the vicinity of the vasculature. It remains to be seen if the peptide requires a leaky tumor vasculature in order to reach this "meta-vascular" target. Leaky vasculature is a phenomenon that occurs homogeneously in tumors xenografted in mice but is a heterogeneous phenomenon in human tumors [141,142].

Hubbell and co-workers have developed extracellular matrix-binding peptides with exciting applications in cancer therapy by imitating natural ligands [143–146]. An ECM-binding peptide derived from the placenta growth factor (PlGF-2), dubbed PlGF-2$_{122–144}$ (sequence: RRRPKGRGKRRREKQRPTDCHL) bound to fibronectin, fibrinogen, osteopontin, vitronectin, and collagens I, II, III and IV with a KD in the low nM range for fibronectin I and collagen I. The peptide was coupled to the immune checkpoint inhibitors anti-CTLA4 and anti-PD-L1, which enhanced their tumor retention and increased their therapeutic effect [147].

Bicycle Therapeutics has developed a peptide-drug conjugate (named BT1718) that targets matrix metalloproteinase-14 (MMP-14), an enzyme that is over-expressed in certain solid tumors [148]. BT1718 consists of a bicyclic ligand coupled to maytansinoid (a microtubule polymerization inhibitor) through a disulfide cleavable linker. BT1718 binds with high affinity ($K_D \approx 1.5$ nM) to MMP-14 and Phase I/IIa trials are underway in patients with advanced solid tumors (triple negative breast cancer and non-small cell lung cancer) (clinical trials identifier: NCT03486730). The ECM-homing peptides described here are summarized in Table 3.

Table 3. ECM-homing peptides.

Peptide Name	Sequence/ Structure	Ref	Identification	Advantages
DAG	CDAGRKQKC (disulfide cyclized)	[20]	In vivo phage display in Alzheimer mice	* Robust homing in patient-derived glioblastoma * Known receptor (CTGF)
ZD2	CTVRTSADC (disulfide cyclized)	[139]	In vitro phage display on recombinant protein	* Known receptor and affinity (Fibronectin extra domain B, K_D:11μM) * PET and MRI active conjugates of ZD2 are being commercially developed by the company Molecular Theranostics
CSG	CSGRRSSKC (disulfide cyclized)	[140]	In vitro phage display on Matrigel ^{TM}	* Robust homing in different mouse models * Known receptor (laminin-nidogen complex)
PlGF-2$_{122-144}$	RRRPKGRGKR RREKQRPTDCHL	[147]	Imitation of natural ligand	* High affinity (low nM K_D) binding to multiple ECM proteins * Proven therapeutic value
BT1718 (Peptide-Drug Conjugate)	Undisclosed (bicyclic peptide coupled to maytansinoid)	[140]	In vitro phage display	* High affinity (low nM K_D) to MMP-14 * In Phase I/IIa clinical trials

6. Tumor Associated Macrophage-Targeting Ligands

Anti-inflammatory or M2-skewed tumor associated macrophages (M2 TAMs) are main effectors of metastasis, angiogenesis, and immunosuppression [149,150]. They derive from circulating monocytes

and are skewed to the M2 phenotype by tumor-secreted cytokines, like interleukin-4 (IL-4) and macrophage-colony stimulating factor (M-CSF). M2 TAMs navigate through the collagen-dense tumor matrix aided by a palette of collagen-interacting proteins such as matrix metalloprotease MMP-9 [151], collagenases [152] and the collagen-endocyting receptor CD206 (mannose receptor, CD206/MRC1). M2 TAMs wander through the ECM forming new blood vessels by secreting VEGF [153] and opening short-lived openings in blood vessels for tumor cells to intravasate [154]. Due to these traits, this subpopulation of macrophages represents a major therapeutic target, and large efforts have been placed in recent years to identify ligands to M2 TAMs.

The company Riptide Biosciences (Vallejo, CA, USA) designed a linear peptide that binds to CD206. The peptide, named RP-182 (sequence: KFRKAFKRFF) consists of alternating hydrophobic and hydrophilic aminoacids. Because the peptide also binds to RelB and CD47, the selectivity of systemically administered RP-182 for M2 TAMs remains to be seen. Interestingly, in a congress abstract [155] the peptide was recently reported to induce phagocytosis and apoptosis in M2 mouse macrophages. This activity could be linked to the conformational change of CD206 produced by RP-182.

Another peptide, named M2Pep (sequence: YEQDPWGVKWWY) was identified in 2013 by Pun and collaborators by performing in vitro biopanning on M2-skewed mouse macrophages [156]. M2pep was coupled to a pro-apoptotic peptide and administered to subcutaneous colon tumor-bearing mice. The treatment was able to extend the survival respect to the untreated mice and suggested that the observed M2pep-targeted TAM depletion was the cause for the enhanced therapeutic benefit. To increase the binding of M2pep to M2 macrophages through avidity, the same authors then synthesized a di-, tri- and tetravalent-peptide conjugate, by coupling M2pep with an added C-terminal cysteine, to maleimide groups on a multi-maleimide scaffold [32]. The tetravalent version had a higher M2/M1 selectivity than its monovalent counterpart, and when conjugated to the pro-apoptotic peptide, the toxicity towards M2 macrophages was augmented in the tetravalent version respect to the monovalent one. In a follow-up study, Pun and co-workers enhanced M2pep by introducing several modifications [26]. First, they disulfide-cyclized it by inserting terminal cysteines. They also noted a rapid cleavage in serum of the bond between tryptophan W10 and W11 of M2pep. Therefore, they substituted W10 for a tyrosine; this increased the serum stability and as a consequence improved the binding. They showed that both disulfide cyclization and substitution of WW for YW resulted in a higher affinity towards M2 macrophages in vitro. The authors also added a three D-lysines (kkk) spacer at the C-terminus to improve the serum stability, although no rationale was provided for this modification. Despite the facts that the receptor for M2pep and cyclicM2pep(RY) have not been determined, that they are hydrophobic and must be dissolved in 10% DMSO, and that binding to human M2 macrophages has not been shown, these two peptides represent promising M2 TAM targeting ligands, as demonstrated by their high in vitro selectivity.

We identified in 2017 a CD206-binding peptide by performing phage display on mice with metastatic breast cancer [157]. The peptide, termed UNO (disulfide cyclized CSPGAKVRC), homed and internalized in M2 TAMs of solid tumors of different models [157]. We further identified the minimal binding motif of UNO to CD206 to be CSPGAK (termed mUNO), which interestingly holds a sequence that is present in all CD206-binding collagens. The peptide mUNO also showed homing to M2 TAMs. We recently showed binding of mUNO to human recombinant CD206 and selectivity of the peptide for human M2 macrophages derived from primary monocytes. Modeling studies of mUNO and human CD206 showed that the peptide interacts with a binding pocket on CD206 to which no other ligand has been reported [158]. This binding pocket lies between C-type lectin domain 1 and C-type lectin domain 2. Modeling and also experimental binding studies showed that mUNO and mannose do not compete for the same binding site. This renders mUNO more specific than mannose-based ligands, which bind to other mannose-binding proteins, like CD209 [159,160]. The M2 TAM-targeting agents described in this review are summarized in Table 4.

Table 4. M2 TAM-targeting agents.

Ligand Name	Sequence	Reference	Identification	Advantages	Disadvantages/Question Marks
RP-182	KFRKAFKRFF	[155]	In silico	▪ Proven efficacy in tumor models in mice	▪ Binds to receptors on other cell types ▪ Not reported if conjugation affects binding
M2pep	YEQDPWGVKWWY	[156]	In vitro phage display	▪ Proven efficacy in tumor models in mice when conjugated to cytotoxic payload	▪ Must be dissolved in 10% DMSO ▪ Receptor unknown ▪ Binding to human M2s unknown
cyclic M2pep(RY)	CGYEQDPWG VRYWYGCkkk	[26]	Rational modification of M2pep	▪ Thoroughly validated specifity to M2 mouse macrophages	▪ Must be dissolved in 10% DMSO ▪ Receptor unknown ▪ Binding to human M2s unknown
Mannose		[161]	Natural ligand of CD206	▪ Conjugation does not affect specificity	▪ The receptor is also present in healthy skin and intestine
mUNO	CSPGAK	[157,158]	In vivo phage display	▪ Conjugation through its N-terminus and also its Cysteine does not affect specificity ▪ Binds to mouse and human CD206 ▪ Does not compete with mannose ▪ Highly specific to M2 TAMs of different solid tumors in mice	▪ In vivo efficacy unpublished

7. Non-Peptidic Ligands

Low and colleagues reported in 1991 that macromolecules could be shuttled inside cells using the folic acid receptor [162]. This small molecule, also known as vitamin B9, has since been used as a drug delivery vehicle, coupled to macromolecules, liposomes, radioactive imaging agents, chemotherapy drugs and other small molecules [163–165]. The folate receptor is reported to be overexpressed in approximately 40% of human cancers. Two different isoforms of the folate receptor are overexpressed in tumors, and they both bind folic acid with high (nM) affinity. The folate receptor-α is overexpressed on cancer cells and the folate receptor-β isoform is expressed on M2 tumor associated macrophages [166].

A company co-founded by Low, called Endocyte (West Lafayette, IN, USA), performed clinical trials using folate to steer the tubulin-disruptive drug vinblastine into tumors. The folate-vinblastine conjugate, called vintafolide, reached phase III in clinical trials in platinum-resistant ovarian cancer. However, in 2014 the phase III was stopped because vintafolide was unable to increase the progression free survival. A later study [167], found high levels of the multidrug resistance protein P-glycoprotein (PgP) in those patients who were positive for folate receptor but did not respond to the treatment, and the study recommended to exclude patients whose tumors are PgP^{high} from future clinical trials.

A clever immunotherapeutic application of folate targeting has emerged last year from the Low laboratory. In this approach, folate is used to target fluorescein to tumors, and anti-fluorescein-engineered chimeric antigen receptor-T (CAR-T) cells are then administered to the mice. This methodology proved highly effective in treating different tumors grown in mice [168,169].

Small molecule phosphoramidate compounds have been developed to target the prostate specific membrane antigen (PSMA), which is overexpressed in human prostate cancers [170,171]. These consist of a family of compounds with varying affinities, some of which irreversibly bind PSMA [172]. These PSMA binders have been used as radioligands to transport the beta-emitting radioisotope ^{177}Lu, through a dodecanetetraacetic acid (DOTA) moiety conjugated to the ligand. The Novartis company (Basel, Switzerland) has an ongoing phase III clinical trial to treat castration-resistant prostate cancer with tumor targeted radiotherapy, by using 177Lu-PSMA (clinical trial identifier: NCT03511664).

Mannose-containing molecules (mannose Mw: 180Da) can be used for cancer theranostics and vaccines to target the mannose receptor MRC1/CD206 which is overexpressed on pro-tumoral macrophages and also present on dendritic cells. Coating nanoparticles with mannose can increase their uptake in M2 macrophages [161]. In vivo, a few studies claim to target payload to M2 TAM by using mannose, however they do not show if the enhanced tumor accumulation observed is due to M2 TAM capture [173], and other studies do not show the results with the non-mannose-targeted control [174].

Although not a low Mw molecule, the multivalent mannose ligand, Manocept, developed by the company Navidea is worth mentioning here. Manocept coupled to a ^{99}technetium-chelating agent is called γ-tilmanocept, it has a Mw of 18 KDa and an extremely high affinity (K_D: 30 pM) for CD206 [175]. In 2013, the FDA approved the local administration of tilmanocept (with the commercial name of Lymphoseek) as a contrast agent to detect CD206$^+$ macrophages in the lymph node, shown to be a marker of early head and neck and breast cancer [176]. Mannose has also been used to guide polymers to dendritic cells for cancer vaccines [177,178]. As other mannose-binding proteins, like CD209 (DC-SIGN) are highly expressed in the intestinal and skin tissue, mannose is expected to have off-target effects when administered sistemically.

8. Concluding Remarks

We have presented here a number of different techniques for identifying peptidic ligands, to target cancer for therapeutic or diagnostic applications, each of which have advantages and disadvantages, as summarized in Table 5. The oldest and most validated approach is to use phage-displayed peptide libraries of the sort CX$_i$C. Since this yields ligands with low affinity and poor protelytic resistance, the peptides should later be tuned up, to obtain more desirable pharmacological properties. Biopanning

using bicyclic peptide libraries is now taking the leap from promise to reality, as reflected by the clinical advances from Bicycle therapeutics.

Table 5. Different methods to identify peptidic ligands and their advantages/disadvantages.

Identification	Advantages	Disadvantages/Question Marks
Phage Display-Cyclic Library (CX_iC)	■ Well validated for in vitro and in vivo biopanning	■ Affinity and proteolytic resistance generally low
Phage Display-Bicyclic Library (CX_iCX_jC)	■ Yields high affinity ligands	■ Not validated in vivo
Phage Display-Sunflower Trypsin Inhibitor I Library	■ Yields cyclotidic ligand: ■ high affinity ■ possible oral activity	■ Ill-described in the literature
Mirror Image Phage Display	■ Yields peptides with high proteolytic resistance	■ Can only be performed in vitro or in vivo ■ Laborious, requires synthesis of D-protein
Imitation of Natural Binder	■ Straightforward	■ Might bind other receptors in healthy tissue ■ If a peptide, requires finding the minimal binding motif
In silico Identification	■ Cheaper ■ Can yield high affinity ligand	■ Can not probe the protein as is in the disease ■ Will not identify an unexpected biomarker

In dealing with low molecular weight ligands, even if proteolysis and affinity issues are circumvented, care must be taken to avoid a rapid kidney excretion before target-binding has occured. Some of the strategies for prolonging the blood half-life of peptides have been reviewed here. However, a short blood half-life will sometimes be advantageous: when using small targeting agents as radioligands, a quick excretion from the system will minimize the unwanted damage produced by the radioligand while it is in the blood.

Certain failed clinical trials of low Mw targeted agents in cancer, such as cilengitide and vintafolide, force us to remain cautious but should not deter the development of this field. The reasons for those flunks at the phase III can only be speculated on. For cilengitide it was suggested to be a poor pharmacokinetics of the peptide, for vintafolide it was suggested to be due to lack of proper patient stratificacion.

Regarding safety considerations on the targeting agents described, to the best of our knowledge, there have been no studies that report immunogenicity. On the contrary, non-immunogenicity was reported for NGR [179] and iRGD [180] in mice. Other positively charged, linear peptides, similar to some of the ones described here, have also shown no immunogenicity in mice [181]. The safety of RGD-based peptides has been confirmed in humans for the case of cilengitide [182], and is currently being evaluated for the case of iRGD (clinical trial identifier: NCT03517176).

In silico mining of peptidic ligands presents itself as an extremely attractive strategy. In light of recent advances in computing power and artificial intelligence, in silico mining could compete with in vitro biopanning for identifying peptidic binders to known proteins, as it is less costly and provides the possibility to fish out peptides with high affinity and high proteolytic resistance [183]. In this

context, the progress in techniques for elucidating protein structure, like cryo-electron microscopy [184], and for determining protein structure in a live cell environment, like in-Cell NMR spectroscopy [185], are expected to further accelerate and improve the development of in silico biopanning.

In complex systems like tumors, the variables that affect the conformation, accessibility and dimerization of a target protein (pH, reducing environment, concentration of ions), and hence affect binding, can hardly be reproduced and modeled; for these situations it will still be necessary to use in vivo biopanning. Additionally, in virtual mining a known protein is set as the target, which leaves out many unknown and possibly interesting receptors to target in a tumor. Therefore, we believe that at least in the short term, in silico screening will not displace in vivo biopanning but will synergize with it.

References

1. Simón-Gracia, L.; Scodeller, P.; Fuentes, S.S.; Vallejo, V.G.; Ríos, X.; San Sebastián, E.; Sidorenko, V.; Di Silvio, D.; Suck, M.; De Lorenzi, F.; et al. Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice. *Oncotarget* **2018**, *9*, 18682–18697. [CrossRef] [PubMed]

2. Wonder, E.; Simón-Gracia, L.; Scodeller, P.; Majzoub, R.N.; Kotamraju, V.R.; Ewert, K.K.; Teesalu, T.; Safinya, C.R. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome–DNA nanoparticles in vitro and in vivo. *Biomaterials* **2018**. [CrossRef] [PubMed]

3. Scodeller, P. Hyaluronidase and other Extracellular Matrix Degrading Enzymes for Cancer Therapy: New Uses and Nano-Formulations. *J. Carcinog. Mutagen.* **2014**, *5*, 1–5. [CrossRef]

4. Scodeller, P. Extracellular Matrix Degrading Enzymes for Nanocarrier-Based Anticancer Therapy. *Intracell. Deliv.* **2016**, *III*, 49–66.

5. Scodeller, P.; Catalano, P.N.; Salguero, N.; Duran, H.; Wolosiuk, A.; Soler-Illia, G.J.A.A. Hyaluronan degrading silica nanoparticles for skin cancer therapy. *Nanoscale* **2013**, *5*, 9690–9698. [CrossRef] [PubMed]

6. Diop-Frimpong, B.; Chauhan, V.P.; Krane, S.; Boucher, Y.; Jain, R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 2909–2914. [CrossRef]

7. Fadnes, H.O.; Reed, R.K.; Aukland, K. Interstitial fluid pressure in rats measured with a modified wick technique. *Microvasc. Res.* **1977**, *14*, 27–36. [CrossRef]

8. Heldin, C.-H.; Rubin, K.; Pietras, K.; Östman, A. High interstitial fluid pressure—An obstacle in cancer therapy. *Nat. Rev. Cancer* **2004**, *4*, 806–813. [CrossRef]

9. Adams, G.P.; Schier, R.; McCall, A.M.; Simmons, H.H.; Horak, E.M.; Alpaugh, R.K.; Marks, J.D.; Weiner, L.M. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. *Cancer Res.* **2001**. [CrossRef]

10. Hussain, S.; Rodriguez-Fernandez, M.; Braun, G.B.; Doyle, F.J.; Ruoslahti, E. Quantity and accessibility for specific targeting of receptors in tumours. *Sci. Rep.* **2014**. [CrossRef]

11. Smith, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. *Science* **1985**, *228*, 1315–1317. [CrossRef] [PubMed]

12. Smith, G.P.; Scott, J.K. Libraries of Peptides and Proteins Displayed on Filamentous Phage. *Methods Enzymol.* **1993**. [CrossRef]

13. Clackson, T.; Hoogenboom, H.R.; Griffiths, A.D.; Winter, G. Making antibody fragments using phage display libraries. *Nature* **1991**. [CrossRef]

14. Koivunen, E.; Gay, D.A.; Ruoslahti, E. Selection of peptides binding to the α5β1 integrin from phage display library. *J. Biol. Chem.* **1993**, *268*, 20505–20510.

15. O'Neil, K.T.; Hoess, R.H.; Jackson, S.A.; Ramachandran, N.S.; Mousa, S.A.; DeGrado, W.F. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. *Proteins Struct. Funct. Bioinform.* **1992**. [CrossRef]

16. Motti, C.; Nuzzo, M.; Meola, A.; Galfré, G.; Felici, F.; Cortese, R.; Nicosia, A.; Monaci, P. Recognition by human sera and immunogenicity of HBsAg mimotopes selected from an M13 phage display library. *Gene* **1994**. [CrossRef]

17. Pasqualini, R.; Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. *Nature* **1996**. [CrossRef]

18. Teesalu, T.; Sugahara, K.N.; Ruoslahti, E. Mapping of vascular ZIP codes by phage display. *Methods Enzymol.* **2012**, *503*, 35–56.

19. Ruoslahti, E. Tumor penetrating peptides for improved drug delivery. *Adv. Drug Deliv. Rev.* **2017**. [CrossRef]

20. Mann, A.P.; Scodeller, P.; Hussain, S.; Braun, G.B.; Mölder, T.; Toome, K.; Ambasudhan, R.; Teesalu, T.; Lipton, S.A.; Ruoslahti, E. Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. *Nat. Commun.* **2017**, *8*. [CrossRef]

21. Mann, A.P.; Scodeller, P.; Hussain, S.; Joo, J.; Kwon, E.; Gary, B. A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries. *Nat. Commun.* **2016**, *7*, 1–11. [CrossRef]

22. Arap, W.; Kolonin, M.G.; Trepel, M.; Lahdenranta, J.; Cardó-Vila, M.; Giordano, R.J.; Mintz, P.J.; Ardelt, P.U.; Yao, V.J.; Vidal, C.I.; et al. Steps toward mapping the human vasculature by phage display. *Nat. Med.* **2002**. [CrossRef]

23. Zurita, A.J.; Troncoso, P.; Cardó-Vila, M.; Logothetis, C.J.; Pasqualini, R.; Arap, W. Combinatorial Screenings in Patients: The Interleukin-11 Receptor α as a Candidate Target in the Progression of Human Prostate Cancer. *Cancer Res.* **2004**. [CrossRef] [PubMed]

24. Lewis, V.O.; Ozawa, M.G.; Deavers, M.T.; Wang, G.; Shintani, T.; Arap, W.; Pasqualini, R. The lnterleukin-11 receptor a as a candidate ligand-directed target in osteosarcoma: Consistent data from cell lines, orthotopic models, and human tumor samples. *Cancer Res.* **2009**. [CrossRef] [PubMed]

25. Staquicini, F.I.; Cardó-Vila, M.; Kolonin, M.G.; Trepel, M.; Edwards, J.K.; Nunes, D.N.; Sergeeva, A.; Efstathiou, E.; Sun, J.; Almeida, N.F.; et al. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. *Proc. Natl. Acad. Sci. USA* **2011**. [CrossRef]

26. Ngambenjawong, C.; Gustafson, H.H.; Pineda, J.M.; Kacherovsky, N.A.; Cieslewicz, M.; Pun, S.H. Serum stability and affinity optimization of an M2 macrophage-targeting peptide (M2pep). *Theranostics* **2016**. [CrossRef]

27. Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. *FEBS Lett.* **1991**. [CrossRef]

28. Reichart, F.; Horn, M.; Neundorf, I. Cyclization of a cell-penetrating peptide via click-chemistry increases proteolytic resistance and improves drug delivery. *J. Pept. Sci.* **2016**. [CrossRef]

29. Molhoek, E.M.; Van Dijk, A.; Veldhuizen, E.J.A.; Haagsman, H.P.; Bikker, F.J. Improved proteolytic stability of chicken cathelicidin-2 derived peptides by d-amino acid substitutions and cyclization. *Peptides* **2011**. [CrossRef]

30. Walensky, L.D.; Bird, G.H. Hydrocarbon-stapled peptides: Principles, practice, and progress. *J. Med. Chem.* **2014**. [CrossRef]

31. Bird, G.H.; Mazzola, E.; Opoku-Nsiah, K.; Lammert, M.A.; Godes, M.; Neuberg, D.S.; Walensky, L.D. Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. *Nat. Chem. Biol.* **2016**. [CrossRef] [PubMed]

32. Ngambenjawong, C.; Cieslewicz, M.; Schellinger, J.G.; Pun, S.H. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. *J. Control. Release* **2016**, *224*, 103–111. [CrossRef] [PubMed]

33. Duro-Castano, A.; England, R.M.; Razola, D.; Romero, E.; Oteo-Vives, M.; Morcillo, M.A.; Vicent, M.J. Well-defined star-shaped polyglutamates with improved pharmacokinetic profiles as excellent candidates for biomedical applications. *Mol. Pharm.* **2015**. [CrossRef] [PubMed]

34. Jayaraman, N. Multivalent ligand presentation as a central concept to study intricate carbohydrate-protein interactions. *Chem. Soc. Rev.* **2009**. [CrossRef] [PubMed]

35. Saether, O.; Craik, D.J.; Campbell, I.D.; Sletten, K.; Juul, J.; Norman, D.G. Elucidation of the Primary and Three-Dimensional Structure of the Uterotonic Polypeptide Kalata B1. *Biochemistry* **1995**. [CrossRef]

36. Wang, C.K.; Craik, D.J. Designing macrocyclic disulfide-rich peptides for biotechnological applications perspective. *Nat. Chem. Biol.* **2018**, *14*, 417–427. [CrossRef]

37. Weidmann, J.; Craik, D.J. Discovery, structure, function, and applications of cyclotides: Circular proteins from plants. *J. Exp. Bot.* **2016**. [CrossRef]

38. White, A.M.; Craik, D.J. Discovery and optimization of peptide macrocycles. *Expert Opin. Drug Discov.* **2016**. [CrossRef]

39. Craik, D.J.; Du, J. Cyclotides as drug design scaffolds. *Curr. Opin. Chem. Biol.* **2017**. [CrossRef]

40. Boy, R.G.; Mier, W.; Nothelfer, E.M.; Altmann, A.; Eisenhut, M.; Kolmar, H.; Tomaszowski, M.; Krämer, S.; Haberkorn, U. Sunflower trypsin inhibitor 1 derivatives as molecular scaffolds for the development of novel peptidic radiopharmaceuticals. *Mol. Imaging Biol.* **2010**. [CrossRef]

41. Qiu, Y.; Taichi, M.; Wei, N.; Yang, H.; Luo, K.Q.; Tam, J.P. An Orally Active Bradykinin B1 Receptor Antagonist Engineered as a Bifunctional Chimera of Sunflower Trypsin Inhibitor. *J. Med. Chem.* **2017**. [CrossRef] [PubMed]

42. Durek, T.; Cromm, P.M.; White, A.M.; Schroeder, C.I.; Kaas, Q.; Weidmann, J.; Ahmad Fuaad, A.; Cheneval, O.; Harvey, P.J.; Daly, N.L.; et al. Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1. *J. Med. Chem.* **2018**. [CrossRef] [PubMed]

43. Baum, R.P.; Kulkarni, H.R.; Schuchardt, C.; Singh, A.; Wirtz, M.; Wiessalla, S.; Schottelius, M.; Mueller, D.; Klette, I.; Wester, H.J. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy. *J. Nucl. Med.* **2016**. [CrossRef] [PubMed]

44. Lee, K.C.; Tak, K.K.; Park, M.O.; Lee, J.T.; Woo, B.H.; Yoo, S.D.; Lee, H.S.; DeLuca, P.P. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. *Pharm. Dev. Technol.* **1999**. [CrossRef]

45. DeNardo, S.J.; Yao, Z.; Lam, K.S.; Song, A.; Burke, P.A.; Mirick, G.R.; Lamborn, K.R.; O'Donnell, R.T.; DeNardo, G.L. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. *Clin. Cancer Res.* **2003**, *9*, 3854s–3864s.

46. Park, S.I.; Renil, M.; Vikstrom, B.; Amro, N.; Song, L.W.; Xu, B.L.; Lam, K.S. The use of one-bead one-compound combinatorial library method to identify peptide ligands for α4β1 integrin receptor in non-Hodgkin's lymphoma. *Lett. Pept. Sci.* **2001**. [CrossRef]

47. Tian, R.; Jacobson, O.; Niu, G.; Kiesewetter, D.O.; Wang, Z.; Zhu, G.; Ma, Y.; Liu, G.; Chen, X. Evans blue attachment enhances somatostatin receptor subtype-2 imaging and radiotherapy. *Theranostics* **2018**. [CrossRef]

48. Liu, Z.; Chen, X. Simple bioconjugate chemistry serves great clinical advances: Albumin as a versatile platform for diagnosis and precision therapy. *Chem. Soc. Rev.* **2016**. [CrossRef]

49. Zorzi, A.; Middendorp, S.J.; Wilbs, J.; Deyle, K.; Heinis, C. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. *Nat. Commun.* **2017**. [CrossRef]

50. Zhang, L.; Bulaj, G. Converting Peptides into Drug Leads by Lipidation. *Curr. Med. Chem.* **2012**. [CrossRef]

51. Levy, O.E.; Jodka, C.M.; Ren, S.S.; Mamedova, L.; Sharma, A.; Samant, M.; D'Souza, L.J.; Soares, C.J.; Yuskin, D.R.; Jin, L.J.; et al. Novel exenatide analogs with peptidic albumin binding domains: Potent anti-diabetic agents with extended duration of action. *PLoS ONE* **2014**. [CrossRef] [PubMed]

52. Pang, H.B.; Braun, G.B.; She, Z.G.; Kotamraju, V.R.; Sugahara, K.N.; Teesalu, T.; Ruoslahti, E. A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. *J. Control. Release* **2014**, *175*, 48–53. [CrossRef] [PubMed]

53. Penchala, S.C.; Miller, M.R.; Pal, A.; Dong, J.; Madadi, N.R.; Xie, J.; Joo, H.; Tsai, J.; Batoon, P.; Samoshin, V.; et al. A biomimetic approach for enhancing the in vivo half-life of peptides. *Nat. Chem. Biol.* **2015**. [CrossRef] [PubMed]

54. Schumacher, T.N.M.; Mayr, L.M.; Minor, D.L.; Milhollen, M.A.; Burgess, M.W.; Kim, P.S. Identification of D-peptide ligands through mirror-image phage display. *Science* **1996**. [CrossRef]

55. Heinis, C.; Rutherford, T.; Freund, S.; Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. *Nat. Chem. Biol.* **2009**. [CrossRef]

56. Borgoño, C.A.; Diamandis, E.P. The emerging roles of human tissue kallikreins in cancer. *Nat. Rev. Cancer* **2004**. [CrossRef]

57. Panyayai, T.; Sangsawad, P.; Pacharawongsakda, E.; Sawatdichaikul, O.; Tongsima, S.; Choowongkomon, K. The potential peptides against angiotensin-I converting enzyme through a virtual tripeptide-constructing library. *Comput. Biol. Chem.* **2018**, *77*, 207–213. [CrossRef]

58. Pinter, M.; Jain, R.K. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. *Sci. Transl. Med.* **2017**. [CrossRef]

59. Song, T.; Choi, C.H.; Kim, M.K.; Kim, M.L.; Yun, B.S.; Seong, S.J. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. *Eur. J. Cancer Prev.* **2017**. [CrossRef]

60. Mollica, A.; Zengin, G.; Durdagi, S.; Ekhteiari Salmas, R.; Macedonio, G.; Stefanucci, A.; Dimmito, M.P.; Novellino, E. Combinatorial peptide library screening for discovery of diverse α-glucosidase inhibitors using molecular dynamics simulations and binary QSAR models. *J. Biomol. Struct. Dyn.* **2019**, *37*, 726–740. [CrossRef]

61. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. *J. Med. Chem.* **2006**, *49*, 6177–6196. [CrossRef]

62. Jacobson, M.P.; Pincus, D.L.; Rapp, C.S.; Day, T.J.F.; Honig, B.; Shaw, D.E.; Friesner, R.A. A Hierarchical Approach to All-Atom Protein Loop Prediction. *Proteins Struct. Funct. Bioinform.* **2004**, *55*, 351–367. [CrossRef] [PubMed]

63. Kevin, J.B.; David, E.C.; Huafeng, X.; Ron, O.D.; Michael, P.E.; Brent, A.G.; John, L.K.; Istvan, K.; Mark, A.M.; Federico, D.S.; et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. In Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, Tampa, FL, USA, 11–17 November 2006.

64. Michaeli, A.; Mezan, S.; Kühbacher, A.; Finkelmeier, D.; Elias, M.; Zatsepin, M.; Reed, S.G.; Duthie, M.S.; Rupp, S.; Lerner, I.; et al. Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity. *J. Immunol.* **2018**, *201*, 3383–3391. [CrossRef] [PubMed]

65. Lerner, I.; Goldblum, A.; Rayan, A.; Vardi, A.; Michaeli, A. From finance to molecular modeling algorithms: The risk and return heuristic. *Curr. Top. Pept. Protein Res.* **2017**, *18*, 117–131.

66. Volk-Draper, L.; Hall, K.; Griggs, C.; Rajput, S.; Kohio, P.; DeNardo, D.; Ran, S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. *Cancer Res.* **2014**. [CrossRef] [PubMed]

67. Vukic, V.R.; Vukic, D.V.; Milanovic, S.D.; Ilicic, M.D.; Kanuric, K.G.; Johnson, M.S. In silico identification of milk antihypertensive di- and tripeptides involved in angiotensin I–converting enzyme inhibitory activity. *Nutr. Res.* **2017**, *46*, 22–30. [CrossRef]

68. Cramer, R.D. The inevitable QSAR renaissance. *J. Comput. Mol. Des.* **2012**, *26*, 8. [CrossRef]

69. Klebe, G.; Abraham, U.M.T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. *J. Med. Chem.* **1994**, *37*, 4130–4146. [CrossRef]

70. Murumkar, P.R.; Shinde, A.C.; Sharma, M.K.; Yamaguchi, H.; Miniyar, P.B.Y.M. Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11β-HSD1 inhibitors. *SAR QSAR Environ. Res.* **2016**, *27*, 265–292. [CrossRef]

71. Cherkasov, A.; Muratov, E.N.; Fourches, D.; Varnek, A.; Baskin, I.I.; Cronin, M.; Dearden, J.; Gramatica, P.; Martin, Y.C.; Todeschini, R.; et al. QSAR Modeling: Where Have You Been? Where Are You Going To? *J. Med. Chem.* **2014**, *57*, 4977–5010. [CrossRef]

72. Guitard, E.; Parker, F.; Millon, R.; Abecassis, J.; Tocqué, B. G3BP is overexpressed in human tumors and promotes S phase entry. *Cancer Lett.* **2001**. [CrossRef]

73. Cui, W.; Wei, Z.; Chen, Q.; Cheng, Y.; Geng, L.; Zhang, J.; Chen, J.; Hou, T.; Ji, M. Structure-based design of peptides against G3BP with cytotoxicity on tumor cells. *J. Chem. Inf. Model.* **2010**, *50*, 380–387. [CrossRef] [PubMed]

74. Geng, L.; Wang, Z.; Yang, X.; Li, D.; Lian, W.; Xiang, Z.; Wang, W.; Bu, X.; Lai, W.; Hu, Z.; et al. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. *Theranostics* **2015**, *5*, 1154–1165. [CrossRef] [PubMed]

75. Orlova, A.; Magnusson, M.; Eriksson, T.L.J.; Nilsson, M.; Larsson, B.; Höiden-Guthenberg, I.; Widström, C.; Carlsson, J.; Tolmachev, V.; Ståhl, S.; et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. *Cancer Res.* **2006**. [CrossRef]

76. Raveh, B.; London, N.; Zimmerman, L.; Schueler-Furman, O. Rosetta FlexPepDock ab-initio: Simultaneous folding, docking and refinement of peptides onto their receptors. *PLoS ONE* **2011**, *6*, e18934. [CrossRef]

77. Donsky, E.; Wolfson, H.J. PepCrawler: A fast RRT-based algorithm for high-resolution refinement and binding affinity estimation of peptide inhibitors. *Bioinformatics* **2011**, *27*, 2836–2842. [CrossRef]

78. Trellet, M.; Melquiond, A.S.; Bonvin, A.M. A unified conformational selection and induced fit approach to protein–peptide docking. *PLoS ONE* **2013**, *8*, e58769. [CrossRef]

79. Hetényi, C.; van der Spoel, D. Efficient docking of peptides to proteins without prior knowledge of the binding site. *Protein Sci.* **2009**, *11*, 1729–1737. [CrossRef]

80. Zhou, P.; Jin, B.; Li, H.; Huang, S.Y. HPEPDOCK: A web server for blind peptide-protein docking based on a hierarchical algorithm. *Nucleic Acids Res.* **2018**, *46*, W443–W450. [CrossRef]

81. Yan, C.; Xu, X.; Zou, X. Fully blind docking at the atomic level for protein–peptide complex structure prediction. *Structure* **2016**, *24*, 1842–1853. [CrossRef]

82. Schindler, C.E.; de Vries, S.J.; Zacharias, M. Fully blind peptide–protein docking with pepATTRACT. *Structure* **2015**, *23*, 1507–1515. [CrossRef] [PubMed]

83. Srinivasan, E.; Rajasekaran, R. Rational design of linear tripeptides against the aggregation of human mutant SOD1 protein causing amyotrophic lateral sclerosis. *J. Neurol. Sci.* **2019**, *405*, 116425. [CrossRef] [PubMed]

84. Papa, L.; Manfredi, G.; Germain, D. SOD1, an unexpected novel target for cancer therapy. *Genes Cancer* **2015**. [CrossRef]

85. Ben-Shimon, A.; Niv, M.Y. AnchorDock: Blind and flexible anchor-driven peptide docking. *Structure* **2015**, *23*, 929–940. [CrossRef] [PubMed]

86. Kurcinski, M.; Pawel Ciemny, M.; Oleniecki, T.; Kuriata, A.; Badaczewska-Dawid, A.E.; Kolinski, A.; Kmiecik, S.; Valencia, A. CABS-dock standalone: A toolbox for flexible protein-peptide docking. *Bioinformatics* **2019**, *35*, 4170–4172. [CrossRef] [PubMed]

87. Blaszczyk, M.; Kurcinski, M.; Kouza, M.; Wieteska, L.; Debinski, A.; Kolinski, A.; Kmiecik, S. Modeling of protein-peptide interactions using the CABS-dock web server for binding site search and flexible docking. *Methods* **2016**, *93*, 72–83. [CrossRef] [PubMed]

88. Zhang, Y.; Sanner, M.F. AutoDock CrankPep: Combining folding and docking to predict protein–peptide complexes. *Bioinformatics* **2019**. [CrossRef]

89. Burkoff, N.S.; Várnai, C.; Wells, S.A.; Wild, D.L. Exploring the energy landscapes of protein folding simulations with bayesian computation. *Biophys. J.* **2012**, *102*, 878–886. [CrossRef]

90. Dundas, J.; Ouyang, Z.; Tseng, J.; Binkowski, A.; Turpaz, Y.L.J. CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. *Nucleic Acids Res.* **2006**, *34*, W116–W118. [CrossRef]

91. Shulman-Peleg, A.; Shatsky, M.; Nussinov, R.; Wolfson, H.J. MultiBind and MAPPIS: Webservers for multiple alignment of protein 3D-binding sites and their interactions. *Nucleic Acids Res.* **2008**, *36*, 260–264. [CrossRef]

92. Gabdoulline, R.R.; Wade, R.C.; Walther, D. MolSurfer: A macromolecular interface navigator. *Nucleic Acids Res.* **2003**, *31*, 3349–3351. [CrossRef] [PubMed]

93. Saha, R.P.; Bahadur, R.P.; Pal, A.; Mandal, S.C.P. ProFace: A server for the analysis of the physicochemical features of protein-protein interfaces. *BMC Struct. Biol.* **2006**, *6*, 11.

94. Wang, Y.; Guo, H.; Feng, Z.; Wang, S.; Wang, Y.; He, Q.; Li, G.; Lin, W.; Xie, X.Q.; Lin, Z. PD-1-targeted discovery of peptide inhibitors by virtual screening, molecular dynamics simulation, and surface plasmon resonance. *Molecules* **2019**, *24*, 3784. [CrossRef] [PubMed]

95. Ansar, S.; Vetrivel, U. PepVis: An integrated peptide virtual screening pipeline for ensemble and flexible docking protocols. *Chem. Biol. Drug Des.* **2019**. [CrossRef]

96. Yan, Y.; Zhang, D.I.; Huang, S.-Y. Efficient conformational ensemble generation of protein-bound peptides. *J. Cheminform.* **2017**, *9*, 59. [CrossRef]

97. Trott, O.; Olson, A.J. Autodock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient opti- mization, and multithreading. *J. Comput. Chem.* **2010**, *31*, 455–461. [CrossRef]

98. Ruoslahti, E.; Vaheri, A.; Kuusela, P.; Linder, E. Fibroblast surface antigen: A new serum protein. *BBA Protein Struct.* **1973**. [CrossRef]

99. Pierschbacher, M.D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. *Nature* **1984**, *309*, 30–33. [CrossRef]

100. Pytela, R.; Pierschbacher, M.D.; Ruoslahti, E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. *Cell* **1985**. [CrossRef]

101. Tamkun, J.W.; DeSimone, D.W.; Fonda, D.; Patel, R.S.; Buck, C.; Horwitz, A.F.; Hynes, R.O. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. *Cell* **1986**. [CrossRef]

102. Ruoslahti, E.; Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. *Science* **1987**. [CrossRef] [PubMed]

103. Teesalu, T.; Sugahara, K.N.; Kotamraju, V.R.; Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 16157–16162. [CrossRef]

104. Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Girard, O.M.; Hanahan, D.; Mattrey, R.F.; Ruoslahti, E. Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors. *Cancer Cell* **2009**, *16*, 510–520. [CrossRef] [PubMed]

105. Sugahara, K.N.; Teesalu, T.; Prakash Karmali, P.; Ramana Kotamraju, V.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. *Science* **2010**. [CrossRef] [PubMed]

106. Sugahara, K.N.; Braun, G.B.; de Mendoza, T.H.; Kotamraju, V.R.; French, R.P.; Lowy, A.M.; Teesalu, T.; Ruoslahti, E. Tumor-Penetrating iRGD Peptide Inhibits Metastasis. *Mol. Cancer Ther.* **2015**, *14*, 120–128. [CrossRef] [PubMed]

107. Akashi, Y.; Oda, T.; Ohara, Y.; Miyamoto, R.; Kurokawa, T.; Hashimoto, S.; Enomoto, T.; Yamada, K.; Satake, M.; Ohkohchi, N. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. *Br. J. Cancer* **2014**. [CrossRef]

108. Puig-Saus, C.; Rojas, L.A.; Laborda, E.; Figueras, A.; Alba, R.; Fillat, C.; Alemany, R. IRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. *Gene Ther.* **2014**. [CrossRef]

109. Schmithals, C.; Köberle, V.; Korkusuz, H.; Pleli, T.; Kakoschky, B.; Augusto, E.A.; Ibrahim, A.A.; Arencibia, J.M.; Vafaizadeh, V.; Groner, B.; et al. Improving drug penetrability with iRGD leverages the therapeutic response to sorafenib and doxorubicin in hepatocellular carcinoma. *Cancer Res.* **2015**. [CrossRef]

110. Fadeev, R.; Chekanov, A.; Solovieva, M.; Bezborodova, O.; Nemtsova, E.; Dolgikh, N.; Fadeeva, I.; Senotov, A.; Kobyakova, M.; Evstratova, Y.; et al. Improved anticancer effect of recombinant protein izTRAIL combined with sorafenib and peptide iRGD. *Int. J. Mol. Sci.* **2019**, *20*, 525. [CrossRef]

111. Liu, X.; Lin, P.; Perrett, I.; Lin, J.; Liao, Y.P.; Chang, C.H.; Jiang, J.; Wu, N.; Donahue, T.; Wainberg, Z.; et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. *J. Clin. Investig.* **2017**. [CrossRef]

112. Sugahara, K.N.; Scodeller, P.; Braun, G.B.; De Mendoza, T.H.; Yamazaki, C.M.; Kluger, M.D.; Kitayama, J.; Alvarez, E.; Howell, S.B.; Teesalu, T.; et al. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. *J. Control. Release* **2015**, *212*, 59–69. [CrossRef] [PubMed]

113. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation. *Anticancer Agents Med. Chem.* **2011**. [CrossRef] [PubMed]

114. Yamada, S.; Bu, X.Y.; Khankaldyyan, V.; Gonzales-Gomez, I.; McComb, J.G.; Laug, W.E. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. *Neurosurgery* **2006**. [CrossRef]

115. Stupp, R.; Hegi, M.E.; Neyns, B.; Goldbrunner, R.; Schlegel, U.; Clement, P.M.J.; Grabenbauer, G.G.; Ochsenbein, A.F.; Simon, M.; Dietrich, P.Y.; et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *J. Clin. Oncol.* **2010**. [CrossRef] [PubMed]

116. Stupp, R.; Hegi, M.E.; Gorlia, T.; Erridge, S.C.; Perry, J.; Hong, Y.K.; Aldape, K.D.; Lhermitte, B.; Pietsch, T.; Grujicic, D.; et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. *Lancet. Oncol.* **2014**. [CrossRef]

117. Tucci, M.; Stucci, S.; Silvestris, F. Does cilengitide deserve another chance? *Lancet Oncol.* **2014**. [CrossRef]

118. Bernhagen, D.; Jungbluth, V.; Quilis, N.G.; Dostalek, J.; White, P.B.; Jalink, K.; Timmerman, P. Bicyclic RGD Peptides with Exquisite Selectivity for the Integrin α v β 3 Receptor Using a 'random Design' Approach. *ACS Comb. Sci.* **2019**. [CrossRef]

119. Altmann, A.; Sauter, M.; Roesch, S.; Mier, W.; Warta, R.; Debus, J.; Dyckhoff, G.; Herold-Mende, C.; Haberkorn, U. Identification of a novel ITGαvβ6-binding peptide using protein separation and phage display. *Clin. Cancer Res.* **2017**. [CrossRef]

120. Del Gatto, A.; Zaccaro, L.; Grieco, P.; Novellino, E.; Zannetti, A.; Del Vecchio, S.; Iommelli, F.; Salvatore, M.; Pedone, C.; Saviano, M. Novel and selective αvβ3 receptor peptide antagonist: Design, synthesis, and biological behavior. *J. Med. Chem.* **2006**. [CrossRef]

121. Zannetti, A.; Del Vecchio, S.; Iommelli, F.; Del Gatto, A.; De Luca, S.; Zaccaro, L.; Papaccioli, A.; Sommella, J.; Panico, M.; Speranza, A.; et al. Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with α vβ5. *Clin. Cancer Res.* **2009**. [CrossRef]

122. Farina, B.; De Paola, I.; Russo, L.; Capasso, D.; Liguoro, A.; Del Gatto, A.; Saviano, M.; Pedone, P.V.; Di Gaetano, S.; Malgieri, G.; et al. A Combined NMR and Computational Approach to Determine the RGDechi-hCit-αvβ3 Integrin Recognition Mode in Isolated Cell Membranes. *Chem. A Eur. J.* **2016**. [CrossRef] [PubMed]

123. Cai, W.; Chen, X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. *Anticancer. Agents Med. Chem.* **2006**, *6*, 407–427. [CrossRef] [PubMed]

124. Sloan, E.K.; Pouliot, N.; Stanley, K.L.; Chia, J.; Moseley, J.M.; Hards, D.K.; Anderson, R.L. Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. *Breast Cancer Res.* **2006**. [CrossRef] [PubMed]

125. Burg, M.A.; Pasqualini, R.; Arap, W.; Ruoslahti, E.; Stallcup, W.B. NG2 proteoglycan-binding peptides target tumor neovasculature. *Cancer Res.* **1999**, *59*, 2869–2874.

126. Guan, Y.Y.; Luan, X.; Xu, J.R.; Liu, Y.R.; Lu, Q.; Wang, C.; Liu, H.J.; Gao, Y.G.; Chen, H.Z.; Fang, C. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. *Biomaterials* **2014**. [CrossRef]

127. Svensen, N.; Walton, J.G.A.; Bradley, M. Peptides for cell-selective drug delivery. *Trends Pharmacol. Sci.* **2012**. [CrossRef]

128. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R.A.; Shapiro, L.H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. *Cancer Res.* **2000**, *60*, 722–727.

129. Suwiwat, S.; Ricciardelli, C.; Tammi, R.; Tammi, M.; Auvinen, P.; Kosma, V.; Lebaron, R.G.; Raymond, W.A.; Tilley, W.D.; Horsfall, D.J. Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan and Their Association with Disease Outcome in Node-Negative Breast Cancer. *Clin. Cancer Res.* **2004**, *10*, 2491–2498. [CrossRef]

130. Asimakopoulou, A.P.; Theocharis, A.D.; Tzanakakis, G.N.; Karamanos, N.K. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. *In Vivo* **2008**, *22*, 385–390.

131. Kim, Y.; Lee, H.G.; Dmitrieva, N.; Kim, J.; Kaur, B.; Friedman, A. Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: A mathematical model. *PLoS ONE* **2014**, *9*, e102499. [CrossRef]

132. Carnemolla, B.; Castellani, P.; Ponassi, M.; Borsi, L.; Urbini, S.; Nicolo, G.; Dorcaratto, A.; Viale, G.; Winter, G.; Neri, D.; et al. Identification of a glioblastoma-associated Tenascin-C isoform by a high affinity recombinant antibody. *Am. J. Pathol.* **1999**. [CrossRef]

133. Park, J.; Kim, S.; Saw, P.E.; Lee, I.H.; Yu, M.K.; Kim, M.; Lee, K.; Kim, Y.C.; Jeong, Y.Y.; Jon, S. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging. *J. Control. Release* **2012**. [CrossRef] [PubMed]

134. Pan, L.H.; Beppu, T.; Kurose, A.; Yamauchi, K.; Sugawara, A.; Suzuki, M.; Ogawa, A.; Sawai, T. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. *Neurol. Res.* **2002**. [CrossRef] [PubMed]

135. Yin, D.; Chen, W.; O'Kelly, J.; Lu, D.; Ham, M.; Doan, N.B.; Xie, D.; Wang, C.; Vadgama, J.; Said, J.W.; et al. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. *Int. J. Cancer* **2010**, *127*, 2257–2267. [CrossRef] [PubMed]

136. Ernst, A.; Campos, B.; Meier, J.; Devens, F.; Liesenberg, F.; Wolter, M.; Reifenberger, G.; Herold-Mende, C.; Lichter, P.; Radlwimmer, B. De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. *Oncogene* **2010**. [CrossRef] [PubMed]

137. Röhrich, M.; Zhang, M.; Capper, D.; Wirkner, U.; Trinh, T.; Debus, J.; Timke, C.; Jenne, J.; Huber, P. An Anti-CTGF-antibody Attenuates Tumor Invasion, Delays Tumor-growth, and Prolongs Survival Alone and in Combination with Radiation in an Orthotopic Glioma. *Int. J. Radiat. Oncol.* **2011**. [CrossRef]

138. Lingasamy, P.; Tobi, A.; Haugas, M.; Hunt, H.; Paiste, P.; Asser, T.; Rätsep, T.; Kotamraju, V.R.; Bjerkvig, R.; Teesalu, T. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery. *Biomaterials* **2019**. [CrossRef]

139. Han, Z.; Zhou, Z.; Shi, X.; Wang, J.; Wu, X.; Sun, D.; Chen, Y.; Zhu, H.; Magi-Galluzzi, C.; Lu, Z.R. EDB fibronectin specific peptide for prostate cancer targeting. *Bioconjug. Chem.* **2015**. [CrossRef]

140. Yeow, Y.L.; Kotamraju, V.R.; Wang, X.; Chopra, M.; Azme, N.; Wu, J.; Schoep, T.D.; Delaney, D.S.; Feindel, K.; Li, J.; et al. Immune-mediated ECM depletion improves tumour perfusion and payload delivery. *EMBO Mol. Med.* **2019**, *11*. [CrossRef]

141. Golombek, S.K.; May, J.N.; Theek, B.; Appold, L.; Drude, N.; Kiessling, F.; Lammers, T. Tumor targeting via EPR: Strategies to enhance patient responses. *Adv. Drug Deliv. Rev.* **2018**, *130*, 17–38. [CrossRef]

142. Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? *J. Control. Release* **2016**. [CrossRef] [PubMed]

143. Mochizuki, M.; Güç, E.; Park, A.J.; Julier, Z.; Briquez, P.S.; Kuhn, G.A.; Müller, R.; Swartz, M.A.; Hubbell, J.A.; Martino, M.M. Growth factors with enhanced syndecan binding generate tonic signalling and promote tissue healing. *Nat. Biomed. Eng.* **2019**, 1–13. [CrossRef] [PubMed]

144. Katsumata, K.; Ishihara, J.; Mansurov, A.; Ishihara, A.; Raczy, M.M.; Yuba, E.; Hubbell, J.A. Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies. *Sci. Adv.* **2019**, *5*, eaay1971. [CrossRef] [PubMed]

145. Sasaki, K.; Ishihara, J.; Ishihara, A.; Miura, R.; Mansurov, A.; Fukunaga, K.; Hubbell, J.A. Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. *Sci. Adv.* **2019**. [CrossRef]

146. Ishihara, J.; Ishihara, A.; Sasaki, K.; Lee, S.S.Y.; Williford, J.M.; Yasui, M.; Abe, H.; Potin, L.; Hosseinchi, P.; Fukunaga, K.; et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. *Sci. Transl. Med.* **2019**. [CrossRef]

147. Ishihara, J.; Fukunaga, K.; Ishihara, A.; Larsson, H.M.; Potin, L.; Hosseinchi, P.; Galliverti, G.; Swartz, M.A.; Hubbell, J.A. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. *Sci. Transl. Med.* **2017**. [CrossRef]

148. González, L.O.; Pidal, I.; Junquera, S.; Corte, M.D.; Vázquez, J.; Rodríguez, J.C.; Lamelas, M.L.; Merino, A.M.; García-Mũiz, J.L.; Vizoso, F.J. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. *Br. J. Cancer* **2007**. [CrossRef]

149. Yang, M.; McKay, D.; Pollard, J.W.; Lewis, C.E. Diverse functions of macrophages in different tumor microenvironments. *Cancer Res.* **2018**. [CrossRef]

150. Lewis, C.E.; Harney, A.S.; Pollard, J.W. The Multifaceted Role of Perivascular Macrophages in Tumors. *Cancer Cell* **2016**, *30*, 18–25. [CrossRef]

151. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J.M.; Senior, R.M.; Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. *Cancer Cell* **2002**. [CrossRef]

152. Madsen, D.H.; Bugge, T.H. Imaging collagen degradation in vivo highlights a key role for M2-polarized macrophages in extracellular matrix degradation. *Oncoimmunology* **2013**, *2*, e27127. [CrossRef] [PubMed]

153. Hughes, R.; Qian, B.Z.; Rowan, C.; Muthana, M.; Keklikoglou, I.; Olson, O.C.; Tazzyman, S.; Danson, S.; Addison, C.; Clemons, M.; et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. *Cancer Res.* **2015**, *75*, 3479–3491. [CrossRef] [PubMed]

154. Wyckoff, J.B.; Wang, Y.; Lin, E.Y.; Li, J.F.; Goswami, S.; Stanley, E.R.; Segall, J.E.; Pollard, J.W.; Condeelis, J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. *Cancer Res.* **2007**, *67*, 2649–2656. [CrossRef] [PubMed]

155. Sable, R.; Jaynes, J.; Ronzetti, M.; Guzman, W.; Knotts, Z.; Val, N.; de Morgan, J.; Yates, C.; Bolormaa, B.; Rudloff, U. Abstract B49: Precision targeting of M2-like macrophages by the innate defense regulator RP-182 in pancreatic cancer and noncancerous diseases. *Cancer Res.* **2019**, *79*, B49.

156. Cieslewicz, M.; Tang, J.; Yu, J.L.; Cao, H.; Zavaljevski, M.; Motoyama, K.; Lieber, A.; Raines, E.W.; Pun, S.H. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 15919–15924. [CrossRef] [PubMed]

157. Scodeller, P.; Simón-Gracia, L.; Kopanchuk, S.; Tobi, A.; Kilk, K.; Säälik, P.; Kurm, K.; Squadrito, M.L.; Kotamraju, V.R.; Rinken, A.; et al. Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide. *Sci. Rep.* **2017**, *7*, 1–12. [CrossRef]

158. Asciutto, E.K.; Kopanchuk, S.; Lepland, A.; Simón-Gracia, L.; Aleman, C.; Teesalu, T.; Scodeller, P. Phage-Display-Derived Peptide Binds to Human CD206 and Modeling Reveals a New Binding Site on the Receptor. *J. Phys. Chem. B* **2019**. [CrossRef]

159. Ehlers, S. DC-SIGN and mannosylated surface structures of Mycobacterium tuberculosis: A deceptive liaison. *Eur. J. Cell Biol.* **2010**. [CrossRef]

160. Lasala, F.; Arce, E.; Otero, J.R.; Rojo, J.; Delgado, R. Mannosyl Glycodendritic Structure Inhibits DC-SIGN-Mediated Ebola Virus Infection in cis and in trans. *Antimicrob. Agents Chemother.* **2003**. [CrossRef]

161. Leber, N.; Kaps, L.; Yang, A.; Aslam, M.; Giardino, M.; Klefenz, A.; Choteschovsky, N.; Rosigkeit, S.; Mostafa, A.; Nuhn, L.; et al. α-Mannosyl-Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages. *Macromol. Biosci.* **2019**. [CrossRef]

162. Leamon, C.P.; Low, P.S. Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis. *Proc. Natl. Acad. Sci. USA* **1991**. [CrossRef] [PubMed]

163. Hilgenbrink, A.R.; Low, P.S. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. *J. Pharm. Sci.* **2005**. [CrossRef] [PubMed]

164. Paulos, C.M.; Turk, M.J.; Breur, G.J.; Low, P.S. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. *Adv. Drug Deliv. Rev.* **2004**. [CrossRef] [PubMed]

165. Low, P.S.; Kularatne, S.A. Folate-targeted therapeutic and imaging agents for cancer. *Curr. Opin. Chem. Biol.* **2009**. [CrossRef] [PubMed]

166. Puig-Kröger, A.; Sierra-Filardi, E.; Domínguez-Soto, A.; Samaniego, R.; Corcuera, M.T.; Gómez-Aguado, F.; Ratnam, M.; Sánchez-Mateos, P.; Corbí, A. Folate receptor β is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory Macrophages. *Cancer Res.* **2009**. [CrossRef] [PubMed]

167. Guertin, A.D.; O'Neil, J.; Stoeck, A.; Reddy, J.A.; Cristescu, R.; Haines, B.B.; Hinton, M.C.; Dorton, R.; Bloomfield, A.; Nelson, M.; et al. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. *Mol. Cancer Ther.* **2016**. [CrossRef]

168. Lee, Y.G.; Chu, H.; Lu, Y.; Leamon, C.P.; Srinivasarao, M.; Putt, K.S.; Low, P.S. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. *Nat. Commun.* **2019**. [CrossRef]

169. Lee, Y.G.; Marks, I.; Srinivasarao, M.; Kanduluru, A.K.; Mahalingam, S.M.; Liu, X.; Chu, H.; Low, P.S. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. *Cancer Res.* **2019**. [CrossRef]

170. Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.W.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. *Clin. Cancer Res.* **1997**, *3*, 81–85.

171. Perner, S.; Hofer, M.D.; Kim, R.; Shah, R.B.; Li, H.; Möller, P.; Hautmann, R.E.; Gschwend, J.E.; Kuefer, R.; Rubin, M.A. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. *Hum. Pathol.* **2007**. [CrossRef] [PubMed]

172. Choy, C.J.; Ling, X.; Geruntho, J.J.; Beyer, S.K.; Latoche, J.D.; Langton-Webster, B.; Anderson, C.J.; Berkman, C.E. 177Lu-labeled phosphoramidate-based PSMA inhibitors: The effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. *Theranostics* **2017**. [CrossRef] [PubMed]

173. Locke, L.W.; Mayo, M.W.; Yoo, A.D.; Williams, M.B.; Berr, S.S. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. *Biomaterials* **2012**, *33*, 7785–7793. [CrossRef] [PubMed]

174. Jiang, C.; Cai, H.; Peng, X.; Zhang, P.; Wu, X.; Tian, R. Targeted imaging of tumor-associated macrophages by cyanine 7-labeled mannose in xenograft tumors. *Mol. Imaging* **2017**. [CrossRef] [PubMed]

175. Azad, A.K.; Rajaram, M.V.S.; Metz, W.L.; Cope, F.O.; Blue, M.S.; Vera, D.R.; Schlesinger, L.S. Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206). *J. Immunol.* **2015**, *195*, 2019–2029. [CrossRef]

176. Wallace, A.M.; Hoh, C.K.; Vera, D.R.; Darrah, D.D.; Schulteis, G. Lymphoseek: A molecular radiopharmaceutical for sentinel node detection. *Ann. Surg. Oncol.* **2003**. [CrossRef] [PubMed]

177. Silva, J.M.; Zupancic, E.; Vandermeulen, G.; Oliveira, V.G.; Salgado, A.; Videira, M.; Gaspar, M.; Graca, L.; Préat, V.; Florindo, H.F. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. *J. Control. Release* **2015**. [CrossRef]

178. Conniot, J.; Scomparin, A.; Peres, C.; Yeini, E.; Pozzi, S.; Matos, A.I.; Kleiner, R.; Moura, L.I.F.; Zupančič, E.; Viana, A.S.; et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. *Nat. Nanotechnol.* **2019**. [CrossRef]

179. Di Matteo, P.; Curnis, F.; Longhi, R.; Colombo, G.; Sacchi, A.; Crippa, L.; Protti, M.P.; Ponzoni, M.; Toma, S.; Corti, A. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. *Mol. Immunol.* **2006**. [CrossRef]

180. De, G.; Ko, J.K.; Tan, T.; Zhu, H.; Li, H.; Ma, J. Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment. *Oncotarget* **2014**. [CrossRef]

181. Suhorutsenko, J.; Oskolkov, N.; Arukuusk, P.; Kurrikoff, K.; Eriste, E.; Copolovici, D.M.; Langel, Ü. Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. *Bioconjug. Chem.* **2011**. [CrossRef]

182. Reardon, D.A.; Fink, K.L.; Mikkelsen, T.; Cloughesy, T.F.; O'Neill, A.; Plotkin, S.; Glantz, M.; Ravin, P.; Raizer, J.J.; Rich, K.M.; et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. *J. Clin. Oncol.* **2008**. [CrossRef] [PubMed]

183. Krüger, D.M.; Glas, A.; Bier, D.; Pospiech, N.; Wallraven, K.; Dietrich, L.; Ottmann, C.; Koch, O.; Hennig, S.; Grossmann, T.N. Structure-Based Design of Non-natural Macrocyclic Peptides That Inhibit Protein-Protein Interactions. *J. Med. Chem.* **2017**. [CrossRef] [PubMed]

184. Baker, M. Cryo-electron microscopy shapes up. *Nature* **2018**. [CrossRef] [PubMed]

185. Sakakibara, D.; Sasaki, A.; Ikeya, T.; Hamatsu, J.; Hanashima, T.; Mishima, M.; Yoshimasu, M.; Hayashi, N.; Mikawa, T.; Wälchli, M.; et al. Protein structure determination in living cells by in-cell NMR spectroscopy. *Nature* **2009**. [CrossRef]